MeSH term
Frequency | Condition_Probility | Adenine Phosphoribosyltransferase/*genetics | 24 | 96.0 |
Animals | 53 | 0.0 |
Base Sequence | 36 | 0.0 |
Female | 65 | 0.0 |
Fibroblasts/enzymology | 4 | 2.0 |
Hypoxanthine Phosphoribosyltransferase/genetics | 5 | 6.0 |
Male | 72 | 0.0 |
Mice | 33 | 0.0 |
Mice, Inbred C3H | 4 | 0.0 |
Mice, Inbred C57BL | 6 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Molecular Sequence Data | 29 | 0.0 |
*Point Mutation | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 62 | 0.0 |
T-Lymphocytes/enzymology | 4 | 10.0 |
Adenine Phosphoribosyltransferase/*deficiency/*genetics | 5 | 100.0 |
Adolescent | 14 | 0.0 |
Adult | 34 | 0.0 |
Child | 23 | 0.0 |
Child, Preschool | 22 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Genotype | 13 | 0.0 |
Humans | 166 | 0.0 |
Iceland | 2 | 5.0 |
Infant | 13 | 0.0 |
Kidney/pathology | 2 | 1.0 |
Middle Aged | 19 | 0.0 |
Adenine/*analogs & derivatives/metabolism | 6 | 75.0 |
Adenine Phosphoribosyltransferase/*deficiency/genetics | 18 | 100.0 |
Age Factors | 3 | 0.0 |
Comparative Study | 16 | 0.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Adenine Phosphoribosyltransferase/*deficiency | 24 | 100.0 |
Allopurinol/therapeutic use | 14 | 82.0 |
Recurrence | 2 | 0.0 |
Adenine/*analogs & derivatives/urine | 3 | 100.0 |
Adenine Phosphoribosyltransferase/*deficiency/*genetics/metabolism | 2 | 100.0 |
Heterozygote | 15 | 0.0 |
Mutation | 17 | 0.0 |
Pedigree | 21 | 0.0 |
Polymerase Chain Reaction | 19 | 0.0 |
Sequence Analysis, DNA | 4 | 0.0 |
Adenine Phosphoribosyltransferase/deficiency/*genetics | 15 | 100.0 |
DNA Primers | 5 | 0.0 |
Gene Frequency | 4 | 0.0 |
Heterozygote Detection | 5 | 0.0 |
Japan | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 64 | 0.0 |
Adenine Phosphoribosyltransferase/genetics | 6 | 66.0 |
Blotting, Southern | 13 | 0.0 |
Cell Line | 25 | 0.0 |
DNA Damage/genetics | 2 | 4.0 |
*DNA-Binding Proteins | 2 | 0.0 |
*Endonucleases | 2 | 2.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Transfection | 3 | 0.0 |
*Loss of Heterozygosity | 3 | 0.0 |
T-Lymphocytes/*enzymology | 2 | 3.0 |
Aged | 12 | 0.0 |
Adenine Phosphoribosyltransferase/deficiency/genetics | 3 | 100.0 |
Chondroitinsulfatases/deficiency/*genetics | 2 | 33.0 |
Family Health | 5 | 0.0 |
*Chromosome Mapping | 8 | 0.0 |
Crosses, Genetic | 4 | 0.0 |
Exons | 5 | 0.0 |
Genes, Recessive | 2 | 0.0 |
*Heterozygote | 3 | 0.0 |
Mice, Inbred Strains | 3 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Point Mutation | 6 | 0.0 |
*Recombination, Genetic | 4 | 1.0 |
*Variation (Genetics) | 4 | 0.0 |
Adenine Phosphoribosyltransferase/*chemistry/genetics/metabolism | 2 | 100.0 |
Amino Acid Sequence | 14 | 0.0 |
Binding Sites | 2 | 0.0 |
Crystallization | 5 | 2.0 |
Models, Molecular | 2 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Restriction Mapping | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Adenine/*analogs & derivatives/*metabolism | 2 | 66.0 |
Cloning, Molecular | 10 | 0.0 |
Protein Conformation | 4 | 0.0 |
Cells, Cultured | 9 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Adenine/*analogs & derivatives/analysis | 5 | 100.0 |
English Abstract | 21 | 0.0 |
Alleles | 19 | 0.0 |
Azacitidine/pharmacology | 2 | 4.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Thymidine Kinase/genetics | 2 | 2.0 |
Creatinine/metabolism | 2 | 2.0 |
Disease Models, Animal | 2 | 0.0 |
Reference Values | 6 | 0.0 |
Cattle | 2 | 0.0 |
Chromosome Banding/veterinary | 2 | 33.0 |
Genome | 2 | 0.0 |
Hamsters | 13 | 0.0 |
Hybrid Cells/*enzymology | 2 | 13.0 |
Adenine Phosphoribosyltransferase/*analysis | 2 | 100.0 |
Hypoxanthine Phosphoribosyltransferase/*analysis | 4 | 100.0 |
Purines/*metabolism | 6 | 27.0 |
Urinary Calculi/etiology | 3 | 50.0 |
Adenine Phosphoribosyltransferase/*blood | 7 | 100.0 |
Hemolysis | 2 | 0.0 |
B-Lymphocytes | 2 | 1.0 |
*Germ-Line Mutation | 2 | 0.0 |
Homozygote | 13 | 0.0 |
Polymorphism, Single-Stranded Conformational | 3 | 0.0 |
Urinary Calculi/enzymology/genetics | 2 | 100.0 |
*DNA Repair | 2 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/*genetics | 2 | 4.0 |
Lesch-Nyhan Syndrome/*genetics | 2 | 50.0 |
2-Aminopurine/analogs & derivatives/pharmacology | 5 | 100.0 |
Chromosome Mapping | 7 | 0.0 |
Clone Cells | 3 | 0.0 |
Drug Resistance/genetics | 2 | 1.0 |
*Gene Deletion | 6 | 0.0 |
Microsatellite Repeats | 3 | 0.0 |
T-Lymphocytes/drug effects/enzymology | 3 | 60.0 |
Thioguanine/pharmacology | 2 | 11.0 |
*Chromosomes, Human, Pair 16 | 4 | 1.0 |
DNA Restriction Enzymes | 2 | 0.0 |
Genetic Markers | 6 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Adenine/metabolism | 4 | 23.0 |
DNA/genetics | 6 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
*Mutation | 23 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/*deficiency | 4 | 100.0 |
Allopurinol/pharmacology | 2 | 15.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Purines/metabolism | 6 | 33.0 |
Adenine Phosphoribosyltransferase/*metabolism | 5 | 100.0 |
Chorionic Villi/enzymology | 2 | 15.0 |
Hypoxanthine Phosphoribosyltransferase/*metabolism | 4 | 100.0 |
Lesch-Nyhan Syndrome/*diagnosis/enzymology | 2 | 100.0 |
Pregnancy | 5 | 0.0 |
Adenine/analogs & derivatives/urine | 2 | 100.0 |
Erythrocytes/enzymology | 11 | 2.0 |
Recombination, Genetic | 4 | 0.0 |
Stem Cells | 2 | 1.0 |
Chromosomes, Human, Pair 16/*genetics | 2 | 2.0 |
Adenosine Monophosphate/metabolism | 2 | 18.0 |
Mutagens/pharmacology | 2 | 5.0 |
Tissue Distribution | 2 | 0.0 |
Fibroblasts | 2 | 0.0 |
Karyotyping | 4 | 0.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Introns | 3 | 0.0 |
Kinetics | 12 | 0.0 |
Nucleic Acid Hybridization | 7 | 0.0 |
Chromosome Banding | 2 | 0.0 |
Hybrid Cells | 4 | 0.0 |
DNA/*genetics | 3 | 0.0 |
Adenine Phosphoribosyltransferase/blood | 5 | 100.0 |
Hypoxanthine Phosphoribosyltransferase/blood | 6 | 100.0 |
Purine-Nucleoside Phosphorylase/blood | 2 | 40.0 |
Transcription, Genetic | 2 | 0.0 |
Chromatography, High Pressure Liquid/methods | 4 | 2.0 |
Codon | 2 | 0.0 |
Adenine Phosphoribosyltransferase/metabolism | 4 | 100.0 |
Adenosine Deaminase/metabolism | 2 | 10.0 |
Hypoxanthine Phosphoribosyltransferase/antagonists & inhibitors | 2 | 100.0 |
Purine-Nucleoside Phosphorylase/metabolism | 2 | 16.0 |
Cricetulus | 3 | 0.0 |
Rats | 3 | 0.0 |
Species Specificity | 5 | 0.0 |
Adenine/*analogs & derivatives/analysis/urine | 2 | 100.0 |
Adenine Phosphoribosyltransferase/blood/*deficiency | 4 | 100.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Cell Transformation, Neoplastic/genetics | 2 | 0.0 |
Chromosomes, Human, Pair 16 | 3 | 2.0 |
Drug Resistance | 6 | 0.0 |
Ethyl Methanesulfonate/pharmacology | 2 | 12.0 |
Polymorphism, Genetic | 3 | 0.0 |
DNA Probes | 5 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Nitrogen Mustard Compounds/pharmacology | 2 | 22.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Plasmids | 3 | 0.0 |
Genes, Tumor Suppressor/genetics | 2 | 1.0 |
Asian Continental Ancestry Group/genetics | 2 | 0.0 |
Urinary Calculi/genetics | 3 | 75.0 |
*Alleles | 4 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Adenine Phosphoribosyltransferase/*genetics/metabolism | 3 | 100.0 |
Erythrocytes/*enzymology | 7 | 1.0 |
Pentosyltransferases/metabolism | 2 | 40.0 |
Temperature | 3 | 0.0 |
Time Factors | 3 | 0.0 |
Escherichia coli/genetics | 3 | 0.0 |
DNA/chemistry | 2 | 0.0 |
*Genes, Structural | 5 | 0.0 |
Adenine Phosphoribosyltransferase/analysis | 3 | 100.0 |
Electrophoresis, Agar Gel | 2 | 0.0 |
Hela Cells | 2 | 0.0 |
Lymphocytes/enzymology | 3 | 3.0 |
*Heterozygote Detection | 4 | 3.0 |
Enzyme Tests | 2 | 2.0 |
Adenine Phosphoribosyltransferase/deficiency | 4 | 100.0 |
In Vitro | 2 | 0.0 |
Mutagens | 2 | 6.0 |
Oligonucleotide Probes | 3 | 0.0 |
B-Lymphocytes/enzymology | 2 | 5.0 |
Lymphocytes/*enzymology | 2 | 2.0 |
Pentosyltransferases/*metabolism | 6 | 46.0 |
Prenatal Diagnosis/methods | 2 | 6.0 |
Uric Acid/analysis | 3 | 75.0 |
Mice/*genetics | 2 | 0.0 |
Hypoxanthine Phosphoribosyltransferase/metabolism | 3 | 25.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Pentosyltransferases/*genetics | 10 | 66.0 |
Pentosyltransferases/*deficiency | 30 | 83.0 |
Hypoxanthine Phosphoribosyltransferase/deficiency | 2 | 40.0 |
Heat | 4 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
Pentosephosphates/*blood | 3 | 60.0 |
Phosphoribosyl Pyrophosphate/*blood | 3 | 100.0 |
Adenine/urine | 2 | 100.0 |
European Continental Ancestry Group | 2 | 0.0 |
Phenotype | 4 | 0.0 |
*Transfection | 2 | 0.0 |
Evolution | 2 | 0.0 |
Foxes/*genetics | 2 | 66.0 |
*Genes | 2 | 0.0 |
Adenine/analogs & derivatives/analysis | 3 | 100.0 |
Adenosine Deaminase/blood | 2 | 14.0 |
Erythrocytes/*metabolism | 3 | 1.0 |
Phosphoribosyl Pyrophosphate | 2 | 100.0 |
Urinary Calculi/enzymology/*genetics | 2 | 100.0 |
Pentosyltransferases/*blood | 7 | 100.0 |
Adenine Phosphoribosyltransferase/genetics/*metabolism | 2 | 100.0 |
Phosphoribosyl Pyrophosphate/metabolism | 3 | 75.0 |
Hybrid Cells/enzymology | 2 | 3.0 |
Thymidine Kinase/*genetics | 2 | 4.0 |
Lymphocyte Activation | 3 | 0.0 |
Lymphocytes/*metabolism | 2 | 1.0 |
Gout/*enzymology/genetics/metabolism | 2 | 100.0 |
Pentosephosphates/*metabolism | 2 | 33.0 |
Leukemia, Lymphocytic/*enzymology | 2 | 18.0 |
Lesch-Nyhan Syndrome/enzymology/*genetics | 2 | 66.0 |
Cross Reactions | 2 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Purine-Pyrimidine Metabolism, Inborn Errors/*enzymology | 2 | 66.0 |
Lymphocytes/metabolism | 2 | 0.0 |
Purines/biosynthesis/*metabolism | 2 | 66.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Rabbits/immunology | 2 | 2.0 |
